OR WAIT null SECS
August 02, 2023
Only a significant joint effort across the supply chain will help to make healthcare more sustainable and reduce the impact of climate change on global health.
August 01, 2023
The program aims to aid submissions from external stakeholders and FDA staff.
Biogen’s acquisition of Reata will grant them access to Reata’s FDA-approved treatment for Friedreich’s ataxia.
AstraZeneca, via its subsidiary Alexion Pharmaceuticals, will purchase a portfolio of preclinical rare disease gene therapies from Pfizer in a deal worth up to $1 billion.
The guidance document outlines recommendations to limit potential carcinogenic risk.
July 31, 2023
The new facility is set to utilize and extend SCG's capabilities in advanced cell therapy manufacturing and off-the-shelf human-induced Pluripotent Stem Cell (iPSC) technology.
July 28, 2023
Pandemic, PBM, and other policies on hold during the summer recess.
The expansion project is aimed to be completed in December 2024 and the new facility will be fully operational by 2025.
July 27, 2023
Teva Pharmaceuticals and Alvotech will expand their partnership for the development and commercialization of biosimilar candidates.
Roche will pay up to $2.8 billion for the rights to Alnylam’s RNA-based hypertension therapeutic.